Wild type NRAS

About

Gene context: NRAS

Biomarker Type: Wild type

Present: True


Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Cetuximab
Sensitivity (+) EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Cetuximab, Irinotecan
Sensitivity (+) EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Cetuximab, Fluorouracil, Oxaliplatin
Sensitivity (+) Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Fluorouracil, Oxaliplatin, Panitumumab
Sensitivity (+) Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Fluorouracil, Irinotecan, Panitumumab
Sensitivity (+) Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Fluorouracil, Irinotecan, Panitumumab
Sensitivity (+) Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Panitumumab
Sensitivity (+) EGFR positive, Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Cetuximab
Sensitivity (+) Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Panitumumab
Sensitivity (+) Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Cetuximab, Fluorouracil, Irinotecan
Sensitivity (+) Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Cetuximab, Irinotecan
Sensitivity (+) Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Cetuximab, Irinotecan
Sensitivity (+) Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Fluorouracil, Oxaliplatin, Panitumumab
Sensitivity (+) Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Fluorouracil, Irinotecan, Panitumumab
Sensitivity (+) Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Fluorouracil, Irinotecan, Panitumumab
Sensitivity (+) Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Cetuximab, Fluorouracil, Irinotecan